XTX Topco’s Spero Therapeutics SPRO Stock Holding History

XTX Topco’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$112K	Buy	+50,536	New	+$132K	﹤0.01%	3497
2026 Q1	–	Sell	-15,175	Closed	-$35.4K	–	4353
2025 Q4	$35.4K	Sell	15,175 -18,626	-55%	-$43.2K	﹤0.01%	2916
2025 Q3	$63.5K	Sell	33,801 -750	-2%	-$1.65K	﹤0.01%	2121
2025 Q2	$100K	Buy	+34,551	New	+$49.7K	﹤0.01%	1885
2025 Q1	–	Sell	-30,138	Closed	-$31K	–	3061
2024 Q4	$31K	Buy	+30,138	New	+$35.8K	﹤0.01%	1973
2024 Q2	–	Sell	-15,013	Closed	-$25.8K	–	2428
2024 Q1	$25.8K	Sell	15,013 -50,953	-77%	-$79.9K	﹤0.01%	1583
2023 Q4	$97K	Buy	65,966 +7,598	+13%	+$9.06K	0.02%	1129
2023 Q3	$70.6K	Sell	58,368 -48,016	-45%	-$66.5K	0.01%	1230
2023 Q2	$154K	Sell	106,384 -13,477	-11%	-$23.1K	0.03%	1086
2023 Q1	$174K	Sell	119,861 -226,873	-65%	-$380K	0.04%	994
2022 Q4	$600K	Buy	+346,734	New	+$647K	0.13%	223
2022 Q2	–	Sell	-13,260	Closed	-$115K	–	1088
2022 Q1	$115K	Buy	+13,260	New	+$136K	0.05%	494

Other funds holding SPRO

GSK plc London $602M AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

XTX Topco's SPRO Position: Q2 2026 in Review

XTX Topco opened a new position in Spero Therapeutics (SPRO) in Q2 2026: 50,536 shares worth $112K. The stake represents ﹤0.01% of the portfolio and ranks #3497 among its holdings. This is a return to the name: XTX Topco previously reported a position in SPRO as recently as Q4 2025.

XTX Topco first reported a position in SPRO in Q1 2022 and has held it in 12 quarters since. The position peaked at $600K in Q4 2022. 60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

XTX Topco held 50,536 shares of Spero Therapeutics worth $112K as of Q2 2026.
Spero Therapeutics was a new XTX Topco position in Q2 2026.
Spero Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #3497 holding.
XTX Topco first reported a position in Spero Therapeutics in Q1 2022 and has held it in 12 quarters since.
XTX Topco's Spero Therapeutics position peaked at $600K in Q4 2022.
60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.